This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Kowa Company, Ltd.
Drug Names(s): Beskoa (Japan), SK0403, Suiny (Japan)
Description: SK-0403 is an oral dipeptidyl peptidase inhibitor that improves post-prandial hyperglycemia by increasing levels of a specialized incretin hormone, GLP-1.
Deal Structure: In August 2008, Kowa Company signed a licensing agreement with SANWA KAGAKU KENKYUSHO. Under the terms of agreement, the two companies will be jointly engaged in development and commercialization of SK-0403 for diabetes, in Japan. Kowa company will make a lump-sum payment and milestone payment at the time of the agreement, as well as payment based on the sale of the drug, to SANWA KAGAKU KENKYUSHO.
Partners: Sanwa Kagaku Kenkyusho Co., Ltd.
Additional information available to subscribers only: